Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
Kalifa
C
C
Razafindrakoto
H
H
Vassal
G
G
Contesso
G
G
Vanel
D
D
Edeline
V
V
Valteau
D
D
Lemerle
J
J
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D003609:Dactinomycin; D004317:Doxorubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D002955:Leucovorin; D008297:Male; D008727:Methotrexate; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine
D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002955:Leucovorin; D007069:Ifosfamide; D008727:Methotrexate